Clustering of cardiovascular risk factors and blood pressure control status in hypertensive patients

Internal Medicine

Volumn 49, Issue 15, 2010, Pages 1483-1487

  Ohta, Yuko ^a   Tsuchihashi, Takuya ^a   Onaka, Uran ^a   Hasegawa, Eri ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Blood pressure control; Clustering of cardiovascular risk factors; Hypertensive patients

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; OBESITY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 77956211448     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3406     Document Type: Article

References (24)

1. Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens 14: 83-90, 2000.
2. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352: 1801-1807, 1998.
3. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041, 2001.
4. Zanchetti A, Hansson L, Clement D, et al. Benefit and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 21: 797-804, 2003.
5. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32: 3-107, 2009.
6. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13(Suppl): 3S-10S, 2000.
7. Ohta Y, Tsuchihashi T, Arakawa K, et al. Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in Fukuoka, Japan. Hypertens Res 30: 1077-1082, 2007.
8. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68: 228-236, 2005.
9. Alderman MH, Cohen H, Madhavan S, et al. Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients. Hypertension 34: 144-150, 1999.
10. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; National high blood pressure education program coordinating committee: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206-1252, 2003.
11. Mancia G, De Backer G, Dominiczak A, et al. management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187, 2007.
12. Katayama S, Inaba M, Morita T, et al. Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 23: 601-605, 2000.
13. Souçek M, Widimský J, Lánská V. Control of hypertension in patients with hypertension, diabetes, and impaired fasting glucose by Czech primary care physicians. Kidney Blood Press Res 29: 366- 372, 2006.
14. Boero R, Prodi E, Elia F, et al. How well are hypertension and albuminuria treated in type II diabetic patients? J Hum Hypertens 17: 413-418, 2003.
15. Ohta Y, Tsuruya K, Fujii K, et al. Improvement of blood pressure control in hypertensive patients with renal diseases. Hypertens Res 30: 295-300, 2007.
16. Weycker D, Nichols GA, O'Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 20: 599-607, 2007.
17. Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 38: 2063-2069, 2007.
18. Kadota A, Hozawa A, Okamura T, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity. Diabetes Care 30: 1533- 1538, 2007.
19. Takeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the national cholesterol education program-adult treatment panel III to Japanese men-The Tanno and Sobetsu Study. Hypertens Res 28: 203-208, 2005.
20. Rodriguez-Colon SM, Mo J, Duan Y, et al. Metabolic syndrome clusters and the risk of incident stroke. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 40: 200-205, 2009.
21. Iso H, Sato S, Kitamura A, et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 38: 1744-1751, 2007.
22. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20: 187-191, 2008.
23. Mabuchi H, Kita T, Matsuzaki M, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease. -Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT)-. Circ J 66: 1096-1100, 2002.
24. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361: 1149-1158, 2003.